Citigroup
QTTB icon

Citigroup’s Q32 Bio QTTB Stock Holding History

Citigroup’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-236
Closed -$467 – 6554
2025
Q3 		$467 Sell
236
-1,586
-87% -$3.05K ﹤0.01% 5715
2025
Q2 		$2.71K Sell
1,822
-2,580
-59% -$4.4K ﹤0.01% 5337
2025
Q1 		$7.26K Sell
4,402
-295
-6% -$794 ﹤0.01% 5239
2024
Q4 		$16.2K Buy
4,697
+306
+7% +$9.66K ﹤0.01% 5300
2024
Q3 		$196K Buy
4,391
+3,037
+224% +$112K ﹤0.01% 4356
2024
Q2 		$24.3K Buy
+1,354
New +$32.4K ﹤0.01% 4941
2023
Q1 		– Sell
-3,445
Closed -$78.1K – 5921
2022
Q4 		$78.1K Sell
3,445
-1,474
-30% -$39.1K ﹤0.01% 4117
2022
Q3 		$143K Sell
4,919
-7,312
-60% -$298K ﹤0.01% 3932
2022
Q2 		$434K Buy
12,231
+11,996
+5,105% +$410K ﹤0.01% 3337
2022
Q1 		$13K Sell
235
-492
-68% -$30.6K ﹤0.01% 5406
2021
Q4 		$48K Buy
727
+262
+56% +$25.4K ﹤0.01% 5093
2021
Q3 		$66K Buy
465
+96
+26% +$12.2K ﹤0.01% 4597
2021
Q2 		$48K Sell
369
-1,184
-76% -$148K ﹤0.01% 4852
2021
Q1 		$263K Buy
1,553
+126
+9% +$26.5K ﹤0.01% 3860
2020
Q4 		$290K Buy
1,427
+994
+230% +$192K ﹤0.01% 4696
2020
Q3 		$83K Sell
433
-2,307
-84% -$517K ﹤0.01% 5258
2020
Q2 		$749K Buy
2,740
+1,513
+123% +$403K ﹤0.01% 3855
2020
Q1 		$344K Buy
1,227
+637
+108% +$195K ﹤0.01% 4221
2019
Q4 		$220K Sell
590
-1,421
-71% -$407K ﹤0.01% 5108
2019
Q3 		$655K Sell
2,011
-597
-23% -$203K ﹤0.01% 4086
2019
Q2 		$918K Buy
2,608
+2,327
+828% +$914K ﹤0.01% 3733
2019
Q1 		$140K Buy
281
+49
+21% +$21.9K ﹤0.01% 5439
2018
Q4 		$93K Buy
232
+80
+53% +$30.3K ﹤0.01% 5714
2018
Q3 		$62K Buy
152
+76
+100% +$25.8K ﹤0.01% 6346
2018
Q2 		$28K Buy
+76
New +$27.2K ﹤0.01% 6752

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's QTTB Position: Q4 2025 in Review

Citigroup sold out of Q32 Bio (QTTB) in Q4 2025, closing a stake of 236 shares — an estimated $467 sold.

Citigroup first reported a position in QTTB in Q2 2018 and held it in 25 quarters. The position peaked at $918K in Q2 2019. 52 funds tracked by Wall St. Rank hold QTTB as of Q4 2025.

  • Citigroup reported no remaining Q32 Bio position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 236 Q32 Bio shares in Q4 2025, an estimated $467.
  • Citigroup first reported a position in Q32 Bio in Q2 2018 and held it in 25 quarters.
  • Citigroup's Q32 Bio position peaked at $918K in Q2 2019.
  • 52 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.